- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Blinatumomab – March 2019
Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto®
Last updated
19 July 2019